Table 1 Patients’ characteristics
Total number of patients, n | 56 | ||
|---|---|---|---|
Group A (n = 26) | Group B (n = 13) | Group C (n = 17) | |
Age at time of operation, in years, median (IQR) | 62 (35.3–71.5) | 64 (46–70) | 58 (36–71.5) |
Male sex, n (%) | 23 (88.5) | 10 (76.9) | 13 (76.5%) |
CCI median (range) | 2 (2–5) | 2 (2–5) | 2 (2–5) |
Distribution of hematological malignancies, n (%) | |||
Myeloid neoplasiaa | 1 (3.8) | 3 (23.1) | 6 (35.3) |
Lymphomab | 23 (88.5) | 5 (38.5) | 11 (64.7) |
Plasma cell disorders | 2 (7.7) | 3 (23.1) | 0 |
Other | 0 | 2 (15.4) | 0 |
Disease status, n (%) | |||
Newly diagnosed | 15 (57.7) | 8 (61.5) | 10 (58.8) |
Refractory/relapsed | 11 (42.3) | 5 (38.5) | 7 (41.2) |
Intestinal or mesenteric involvement, n (%) | 18 (69.2) | 5 (38.5) | NA |
Systemic treatment, n (%) | |||
CD20-directed treatment | 11 (42.3) | 5 (38.5) | 3 (17.7) |
Chemotherapy-based treatmentc | 12 (46.2) | 11 (84.6) | 9 (52.9) |
Autologous PBSCT | 1 (3.8) | 0 | 0 |
Allogeneic PBSCT ≤ 100 days prior to surgery | 0 | 3 (23.1) | 4 (23.5) |
Corticosteroids | 11 (42.3) | 6 (46.2) | 5 (29.4) |
Otherd | 1 (3.8) | 1 (7.7) | 1 (5.9) |
Nonee | 10 (38.5) | 1 (7.7) | 4 (23.5) |
Median duration between last systemic treatment and surgery (IQR)f | 21 (8–86) | 23 (18–65) | 29 (17–46) |
Neutropenia ≥ grade 3g | 0 | 4 (22.2) | 2 (11.8) |
Thrombocytopenia ≥ grade 3g | 3 (11.5) | 5 (38.5) | 9 (52.9) |
GvHD prophylaxis or treatment, n (%) | 0 | 3 (23.1) | 3 (17.7) |
Calcineurin-inhibitors | NA | 3 (23.1) | 3 (17.7) |
Corticosteroids | NA | 1 (7.7) | 1 (5.7) |
Mycophenolate mofetil | NA | 0 | 3 (17.7) |
Immunoglobulin therapy | NA | 2 (15.4) | 3 (17.7) |
Unknown | NA | 0 | 1 (5.7) |